Inhibrx Net Worth
Inhibrx Net Worth Breakdown | INBX |
Inhibrx Net Worth Analysis
Inhibrx's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Inhibrx's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Inhibrx's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Inhibrx's net worth analysis. One common approach is to calculate Inhibrx's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Inhibrx's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Inhibrx's net worth. This approach calculates the present value of Inhibrx's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Inhibrx's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Inhibrx's net worth. This involves comparing Inhibrx's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Inhibrx's net worth relative to its peers.
Enterprise Value |
|
To determine if Inhibrx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Inhibrx's net worth research are outlined below:
| Inhibrx had very high historical volatility over the last 90 days | |
| Inhibrx has high likelihood to experience some financial distress in the next 2 years | |
| Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB. | |
| The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M). | |
| Inhibrx currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| Inhibrx has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3 |
Inhibrx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Inhibrx. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inhibrx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Inhibrx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inhibrx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibrx backward and forwards among themselves. Inhibrx's institutional investor refers to the entity that pools money to purchase Inhibrx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Manufacturers Life Insurance Co | 2024-06-30 | 0.0 | Metlife Inc | 2024-06-30 | 0.0 | Hhg Plc | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | State Of Wisconsin Investment Board | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Profund Advisors Llc | 2024-06-30 | 0.0 | Yakira Capital Management, Inc. | 2024-06-30 | 0.0 | Cnh Partners, Llc | 2024-06-30 | 0.0 | Dekabank Deutsche Girozentrale | 2024-06-30 | 26.4 K | Advisor Group Holdings, Inc. | 2024-06-30 | 6.7 K |
Follow Inhibrx's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 203.82 M.Market Cap |
|
Project Inhibrx's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (5.55) | (5.27) |
When accessing Inhibrx's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Inhibrx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Inhibrx's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Inhibrx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibrx. Check Inhibrx's Beneish M Score to see the likelihood of Inhibrx's management manipulating its earnings.
Evaluate Inhibrx's management efficiency
Inhibrx has return on total asset (ROA) of (0.5746) % which means that it has lost $0.5746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.3105) %, meaning that it created substantial loss on money invested by shareholders. Inhibrx's management efficiency ratios could be used to measure how well Inhibrx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.91 in 2024. At this time, Inhibrx's Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 310.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 24.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.92 | 0.97 | |
| Tangible Book Value Per Share | 0.92 | 0.97 | |
| Enterprise Value Over EBITDA | (8.34) | (8.75) | |
| Price Book Value Ratio | 41.17 | 43.23 | |
| Enterprise Value Multiple | (8.34) | (8.75) | |
| Price Fair Value | 41.17 | 43.23 | |
| Enterprise Value | 705.9 M | 614.9 M |
Inhibrx's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Enterprise Value Revenue 5.9463 | Revenue 1.7 M | Quarterly Revenue Growth 2.333 | Revenue Per Share 0.117 | Return On Equity (20.31) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibrx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibrx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibrx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibrx Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of August 2024 Other Reports | ViewVerify |
Inhibrx Earnings per Share Projection vs Actual
Inhibrx Corporate Management
| Leah JD | Corporate VP | Profile | |
| Mark Lappe | Chairman, Founder | Profile | |
| Charbel PharmD | Vice Planning | Profile | |
| BS CPA | Chief Officer | Profile | |
| Jeffrey Jensen | Executive Officer | Profile | |
| Brendan Eckelman | Executive Officer | Profile | |
| Carlos Bais | Executive Sciences | Profile |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.